T Cell News and Research

Latest T Cell News and Research

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Eisai Inc. announced today results from an investigational Phase 2 trial which showed that lenvatinib, when used in combination with everolimus, significantly extended progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) versus everolimus alone.

1 Jun 2015

Asterias reports positive data from AST-VAC1 Phase 2 trial for intermediate, high risk AML

Asterias Biotherapeutics, Inc., a biotechnology company focused on the emerging field of regenerative medicine, today announced positive, new, long-term follow-up data from a Phase 2 clinical trial of AST-VAC1 in patients with intermediate and high risk acute myelogenous leukemia (AML).

1 Jun 2015

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.

1 Jun 2015

Abbvie presents venetoclax Phase 1 results in patients with multiple myeloma at ASCO 2015

AbbVie, a global biopharmaceutical company, today announced that results from a Phase 1b trial of investigational venetoclax, a novel inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, in combination with bortezomib and dexamethasone, showed an 83 percent overall response rate (n=5/6) in bortezomib-naive patients with relapsed/refractory (R/R) multiple myeloma, including two patients who achieved complete responses.1 These data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, May 31, in Chicago.

1 Jun 2015

AstraZeneca presents preliminary data from AZD6094-AZD9291 combination trial for treatment of NSCLC

Hutchison China MediTech Limited, today announces that AstraZeneca AB, Hutchison MediPharma Limited's collaboration partner, presented preliminary data from the ongoing Phase Ib clinical trial of HMP's c-Met inhibitor savolitinib (AZD6094) combined with AstraZeneca's drug candidate AZD9291 in non-small cell lung cancer.

1 Jun 2015

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Novartis today announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) compared to Tafinlar monotherapy alone.

1 Jun 2015

Game changing, breakthrough early cancer detection technology presented at ASCO 2015

Anpac Bio-Medical Science Co., Ltd., Chief Executive Officer and Scientist Dr. Chris Yu and the Anpac research team are introducing what the 2015 Nobel Prize Laureate Summit on Biomedical Science (NPLS) organizers published as, "game changing" and "breakthrough" early cancer detection technology research results at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, May 29 – June 2, 2015.

1 Jun 2015

Scientists one step closer to understanding how brain regulates memory and mood

Scientists are one step closer to understanding how the brain regulates memory and mood, thanks to the discovery of two distinct types of stem cells.

1 Jun 2015

Scientists develop human cortical spheroids

A patient tormented by suicidal thoughts gives his psychiatrist a few strands of his hair. She derives stem cells from them to grow budding brain tissue harboring the secrets of his unique illness in a petri dish. She uses the information to genetically engineer a personalized treatment to correct his brain circuit functioning. Just Sci-fi? Yes, but...

1 Jun 2015

People with common form of lung cancer can benefit from nivolumab drug

In a head-to-head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous-non-small cell lung cancer who received nivolumab lived, on average, 3.2 months longer than those receiving chemotherapy.

1 Jun 2015

ASCO 2015: UH Seidman Cancer Center researchers present data from several new studies

Researchers from University Hospitals Case Medical Center Seidman Cancer Center and Case Western Reserve University School of Medicine will present data from several new studies, including a study evaluating a potential novel combination treatment for cancer patients with advanced solid tumors and a first-of-its-kind analysis of gene mutations in small cell lung cancer (SCLC), at the 51st American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago.

1 Jun 2015

Process of aging could be delayed in human cell lines

Can the process of aging be delayed or even reversed? Research led by specially appointed Professor Jun-Ichi Hayashi from the University of Tsukuba in Japan has shown that, in human cell lines at least, it can. They also found that the regulation of two genes involved with the production of glycine, the smallest and simplest amino acid, is partly responsible for some of the characteristics of aging.

1 Jun 2015

Two grants to bolster research on why ovarian cancer is resistant to chemotherapy

Determining which strains of cancer will eventually become resistant to chemotherapy could be key in figuring out more effective and targeted forms of treatment. Finding the genes responsible for chemo-resistance is what Jeremy Chien, Ph.D., member of the Cancer Biology Program at The University of Kansas Cancer Center, is looking to do with an innovative system that draws inspiration from the early days of cancer gene research.

1 Jun 2015

Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Promising clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients.

1 Jun 2015

Secret to the life-long activity of a stem cell niche

The roots of a plant are constantly growing, so that they can provide the plant with water and minerals while also giving it a firm anchor in the ground. Responsible for these functions are pluripotent stem cells. In order to avoid differentiation and to remain pluripotent, these stem cells are dependent on signals from their neighbouring cells.

1 Jun 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015.

1 Jun 2015

PGDx introduces ImmunoSelect-R service to support development of immuno-oncology cancer therapies

Personal Genome Diagnostics, Inc., a provider of advanced cancer genome analysis and testing services, today announced the launch of its ImmunoSelect-R service designed to identify mutant neoantigens and support development of immuno-oncology cancer therapies.

1 Jun 2015

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from three studies that demonstrate the utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in facilitating comparisons between tumors that share histological features.

1 Jun 2015

Study findings underscore importance of PD-1/PD-L1 expression in oncogenic signaling pathways

Caris Life Sciences® today announced the presentation of data from two studies in which researchers utilized Caris Molecular Intelligence®, the company's panomic, comprehensive tumor profiling service, to identify potential therapeutic targets in patients with colorectal and pancreatic cancer subtypes, based on expression of the programmed cell death protein 1 (PD-1) and its ligand, PD-L1.

1 Jun 2015

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis.

1 Jun 2015

T Cell News and Research

Latest T Cell News and Research

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Asterias reports positive data from AST-VAC1 Phase 2 trial for intermediate, high risk AML

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Abbvie presents venetoclax Phase 1 results in patients with multiple myeloma at ASCO 2015

AstraZeneca presents preliminary data from AZD6094-AZD9291 combination trial for treatment of NSCLC

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Game changing, breakthrough early cancer detection technology presented at ASCO 2015

Scientists one step closer to understanding how brain regulates memory and mood

Scientists develop human cortical spheroids

People with common form of lung cancer can benefit from nivolumab drug

ASCO 2015: UH Seidman Cancer Center researchers present data from several new studies

Process of aging could be delayed in human cell lines

Two grants to bolster research on why ovarian cancer is resistant to chemotherapy

Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Secret to the life-long activity of a stem cell niche

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

PGDx introduces ImmunoSelect-R service to support development of immuno-oncology cancer therapies

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Study findings underscore importance of PD-1/PD-L1 expression in oncogenic signaling pathways

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

Immunology eBook

Directed enzyme evolution and the Nobel Prize: Making enzymes evolve in the lab

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Directed enzyme evolution and the Nobel Prize: Making enzymes evolve in the lab

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Newsletters you may be interested in